New drug IACS-6274 shows promise in phase I clinical trial treating patients with advanced ovarian cancer (IMAGE)
Caption
Computed tomography (CT) scans from a platinum-resistant high-grade ovarian cancer patient who achieved a -49.5% radiological reduction in tumour volume from baseline (left scan) and was treated for more than 15 months on trial.
Credit
Prof. Tim Yap, The University of Texas MD Anderson Cancer Center
Usage Restrictions
None
License
Licensed content